Market Cap
kr663.5m
Last Updated
2019/10/14 21:31 UTC
Data Sources
Company Financials +
Executive Summary
Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark.
Snowflake
Fundamentals
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Saniona's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
9.1%
SANION
1.8%
SE Biotechs
1.9%
SE Market
1 Year Return
-24.0%
SANION
-18.0%
SE Biotechs
9.6%
SE Market
Return vs Industry: SANION underperformed the Swedish Biotechs industry which returned -18% over the past year.
Return vs Market: SANION underperformed the Swedish Market which returned 9.6% over the past year.
Shareholder returns
| SANION | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.1% | 1.8% | 1.9% |
| 30 Day | 21.0% | -1.9% | -0.3% |
| 90 Day | 31.2% | -11.7% | 0.7% |
| 1 Year | -21.9%-24.0% | -17.5%-18.0% | 14.3%9.6% |
| 3 Year | -33.9%-35.8% | 29.5%19.2% | 31.5%11.9% |
| 5 Year | 199.1%176.3% | 66.9%68.0% | 66.2%30.8% |
Price Volatility Vs. Market
How volatile is Saniona's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does Saniona AB (publ) (STO:SANION) Have A Volatile Share Price?1 month ago | Simply Wall St
Is Saniona AB (publ) (STO:SANION) Overpaying Its CEO?1 month ago | Simply Wall St
Could The Saniona AB (publ) (STO:SANION) Ownership Structure Tell Us Something Useful?Valuation
Is Saniona undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: SANION (SEK23.9) is trading below our estimate of fair value (SEK376.25)
Significantly Undervalued: SANION is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SANION is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SANION is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate SANION's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SANION is overvalued based on its PB Ratio (8.3x) compared to the SE Biotechs industry average (3.8x).
Next Steps
Future Growth
How is Saniona forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
72.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SANION is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SANION is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SANION is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SANION's revenue (48.7% per year) is forecast to grow faster than the Swedish market (4.5% per year).
High Growth Revenue: SANION's revenue (48.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if SANION's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Saniona performed over the past 5 years?
-37.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: SANION is unprofitable, and losses have increased over the past 5 years at a rate of -37.7% per year.
Accelerating Growth: Unable to compare SANION's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SANION is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.4%).
Return on Equity
High ROE: SANION has a negative Return on Equity (-76.22%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: SANION is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: SANION is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Saniona's financial position?
Financial Position Analysis
Short Term Liabilities: SANION's short term assets (SEK110.3M) exceeds its short term liabilities (SEK59.4M)
Long Term Liabilities: SANION's short term assets (110.3M) exceeds its long term liabilities (2.9M)
Debt to Equity History and Analysis
Debt Level: SANION's debt to equity ratio (15.2%) is considered satisfactory
Reducing Debt: Insufficient data to determine if SANION's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: SANION has a low level of unsold assets or inventory.
Debt Coverage by Assets: SANION's debt is covered by short term assets (assets are 10.506850x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SANION has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SANION has less than a year of cash runway if free cash flow continues to reduce at historical rates of -40% each year
Next Steps
Dividend
What is Saniona's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate SANION's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SANION's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if SANION's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SANION's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SANION's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
What is the CEO of Saniona's salary, the management and board of directors tenure and is there insider trading?
8.8yrs
Average management tenure
CEO
Jørgen Drejer (64yo)
5.8yrs
Tenure
kr1,687,000
Compensation
Mr. Jørgen Drejer, Ph.D., founded Saniona AB (Alternate name-Aniona) in 2011 and has been its Chief Executive Officer since 2014. Mr. Drejer is a Co-founder of NeuroSearch. He has been Member of the Execut ...
CEO Compensation Analysis
Compensation vs. Market: Jørgen's total compensation ($USD171.63K) is about average for companies of similar size in the Swedish market ($USD124.61K).
Compensation vs Earnings: Jørgen's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
8.8yrs
Average Tenure
62.5yo
Average Age
Experienced Management: SANION's management team is seasoned and experienced (8.8 years average tenure).
Board Age and Tenure
2.9yrs
Average Tenure
64yo
Average Age
Experienced Board: SANION's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Claus Bræstrup (74yo)
Co-Founder & Director
- Tenure: 5.8yrs
Jørgen Drejer (64yo)
Co-Founder
- Tenure: 5.8yrs
- Compensation: kr1.69m
Thomas Feldthus (59yo)
Co-Founder
- Tenure: 8.8yrs
- Compensation: kr2.20m
Palle Christophersen (61yo)
Co-Founder & Chief Scientific Officer
- Tenure: 8.8yrs
- Compensation: kr1.35m
Karin Nielsen
Vice President of Operations and Director of In Vivo Pharmacology
- Tenure: 3.6yrs
Board Members
Don deBethizy (69yo)
Chairman of the Board
- Tenure: 1.8yrs
- Compensation: kr1.15m
Claus Bræstrup (74yo)
Co-Founder & Director
- Tenure: 5.8yrs
Carl Sundberg (61yo)
Director
- Tenure: 4.1yrs
- Compensation: kr145.00k
Jørgen Drejer (64yo)
Co-Founder
- Tenure: 5.8yrs
- Compensation: kr1.69m
Ed Saltzman (64yo)
Director
- Tenure: 0.4yrs
Anna Ljung (39yo)
Director
- Tenure: 1.8yrs
- Compensation: kr184.00k
Company Information
Saniona AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Saniona AB (publ)
- Ticker: SANION
- Exchange: OM
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr663.544m
- Shares outstanding: 27.76m
- Website: https://www.saniona.com
Number of Employees
Location
- Saniona AB (publ)
- Baltorpvej 154
- Ballerup
- Capital Region of Denmark
- 2750
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SANION | OM (OMX Nordic Exchange Stockholm) | Yes | Share Capital | SE | SEK | Apr 2014 |
| 0RQJ | LSE (London Stock Exchange) | Yes | Share Capital | GB | SEK | Apr 2014 |
| 30S | DB (Deutsche Boerse AG) | Yes | Share Capital | DE | EUR | Apr 2014 |
Biography
Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug can ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/14 21:31 |
| End of Day Share Price | 2019/10/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.